61,211 results match your criteria hcc


Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade.

Transl Oncol 2021 May 8;14(8):101116. Epub 2021 May 8.

Department of anesthesiology, Linyi Central Hospital, Shandong 276400, China. Electronic address:

Bcl-2 family proteins play critical roles in regulating lymphocyte development and maintain homeostasis, and have also been proved to be involved in various cancer types development. However, the role of Bcl-2 in hepatocellular carcinoma (HCC) development has not been clearly studied. Here, we reported the pan-Bcl-2 inhibitor, obatoclax could directly inhibit HCC growth in vitro. Read More

View Article and Full-Text PDF

A Multimodality-Contribution-Aware TripNet for Histologic Grading of Hepatocellular carcinoma.

IEEE/ACM Trans Comput Biol Bioinform 2021 May 11;PP. Epub 2021 May 11.

Hepatocellular carcinoma (HCC) is a type of primary liver malignant tumor with a high recurrence rate and poor prognosis even undergoing resection or transplantation. Accurate discrimination of the histologic grades of HCC plays a critical role in the management and therapy of HCC patients. In this paper, we discuss a deep learning-based diagnostic model for HCC histologic grading with multimodal Magnetic Resonance Imaging (MRI) images to overcome the problem of limited well-annotated data and extract the discriminated fusion feature referring to the clinical diagnosis experience of radiologists. Read More

View Article and Full-Text PDF

Integrated profiling identifies ITGB3BP as prognostic biomarker for hepatocellular carcinoma.

Bosn J Basic Med Sci 2021 Apr 12. Epub 2021 Apr 12.

Department of Epidemiology and Statistics, School of Public Health, Guangxi Medical University, Nanning, China; Key Laboratory of High-Incidence-Tumor Prevention and Treatment, Guangxi Medical University, Ministry of Education, Nanning, China.

Hepatocellular carcinoma (HCC) is a highly malignant tumor. In this study, we sought to identify a novel biomarker for HCC by analyzing transcriptome and clinical data. The R software was used to analyze the differentially expressed genes (DEGs) in the datasets GSE74656 and GSE84598 downloaded from the Gene Expression Omnibus database, followed by a functional annotation. Read More

View Article and Full-Text PDF

MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.

Cell Oncol (Dordr) 2021 May 11. Epub 2021 May 11.

Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.

Purpose: Lenvatinib is a long-awaited alternative to Sorafenib for first-line targeted therapy of patients with advanced hepatocellular carcinoma (HCC). However, resistance to Lenvatinib results in tumor progression and has become a major obstacle to improving the prognosis of HCC patients. Exploring the mechanisms underlying Lenvatinib resistance is considered essential for the treatment of advanced HCC. Read More

View Article and Full-Text PDF

Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma.

Radiology 2021 May 11:203614. Epub 2021 May 11.

From the Departments of Radiology (Z.F., H.L., H.Z., Y.J., Q.L., W.W., P.R.) and Pathology (Q.C.), The Third Xiangya Hospital of Central South University, No. 138 Tongzipo Road, Changsha 410013, China.

Background Macrotrabecular-massive (MTM) subtype and vessels encapsulating tumor clusters (VETC) pattern of hepatocellular carcinoma (HCC) are associated with unfavorable prognosis. Purpose To estimate the potential of preoperative CT in the prediction of MTM subtype and VETC pattern. Materials and Methods Patients who underwent surgical resection or liver transplant and preoperative CT for HCC between January 2015 and June 2018 were retrospectively included in the primary cohort. Read More

View Article and Full-Text PDF

Knockdown of CENPW Inhibits Hepatocellular Carcinoma Progression by Inactivating E2F Signaling.

Technol Cancer Res Treat 2021 Jan-Dec;20:15330338211007253

Department of Infectious Diseases, Qingdao No.6 People's Hospital, Qingdao, Shandong, People's Republic of China.

Aim: This study aimed to evaluate the effects of centromere protein W (CENPW, also known as CUG2) in hepatocellular carcinoma (HCC).

Methods: CENPW expression in HCC tissues and cells was detected by RT-qPCR assay. CCK-8 and colony formation assay were used to assess cell proliferation. Read More

View Article and Full-Text PDF

FDA Approval Summary: Nivolumab plus ipilimumab for the treatment of patients with hepatocellular carcinoma previously treated with sorafenib.

Oncologist 2021 May 11. Epub 2021 May 11.

Center for Drug Evaluation and Research, U.S. Food and Drug Administration.

On March 10, 2020, the FDA granted accelerated approval to nivolumab in combination with ipilimumab for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. The recommended approved dosage was nivolumab 1 mg/kg intravenously (IV) plus ipilimumab 3 mg/kg IV every 3 weeks for four cycles, followed by nivolumab 240 mg IV every 2 weeks. The approval was based on data from Cohort 4 of CHECKMATE-040, which randomized patients with advanced unresectable or metastatic HCC previously treated with or who were intolerant to sorafenib to receive one of three different dosing regimens of nivolumab in combination with ipilimumab. Read More

View Article and Full-Text PDF

CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.

Clin Pract (Lond) 2021 ;18(2):1626-1632

Department of Surgery, Liver Transplantation Institute, Inonu University, Turkey.

Background: Inflammation and its markers are considered prognostically important for many cancers, including Hepatocellular Carcinoma (HCC). However, it is not really clear which markers are the best.

Aims: To assess in a cohort of prospectively-evaluated HCC patients who were treated with liver transplant and whose survival was known, multiple commonly used inflammatory markers in relation to survival and to both clinical and tumor aggressiveness parameters. Read More

View Article and Full-Text PDF
January 2021

FMRP regulates STAT3 mRNA localization to cellular protrusions and local translation to promote hepatocellular carcinoma metastasis.

Commun Biol 2021 May 10;4(1):540. Epub 2021 May 10.

Cancer Metastasis Alert and Prevention Center, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, National & Local Joint Biomedical Engineering Research Center on Photodynamic Technologies, State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou, China.

Most hepatocellular carcinoma (HCC)-associated mortalities are related to the metastasis of cancer cells. The localization of mRNAs and their products to cell protrusions has been reported to play a crucial role in the metastasis. Our previous findings demonstrated that STAT3 mRNA accumulated in the protrusions of metastatic HCC cells. Read More

View Article and Full-Text PDF

Surgical Outcome of Pulmonary Metastasectomy for Hepatocellular Carcinoma Recurrence in Liver Transplant Patients.

Ann Transplant 2021 May 11;26:e930383. Epub 2021 May 11.

Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

BACKGROUND Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) results in poor survival outcome. This study assessed the clinical outcomes of pulmonary metastasectomy in LT recipients with pulmonary metastasis of HCC in a high-volume transplant center and analyzed factors prognostic of survival following metastasectomy. MATERIAL AND METHODS This study analyzed outcomes in 52 patients who underwent pulmonary resection due to pulmonary metastasis as the first recurrence of HCC after LT from January 2004 to December 2017 in a single center. Read More

View Article and Full-Text PDF

Combined detection of circulating tumor cells, α-fetoprotein heterogene-3 and α-fetoprotein in the early diagnosis of HCC for the prediction of efficacy, prognosis, recurrence after microwave ablation.

Infect Agent Cancer 2021 May 10;16(1):28. Epub 2021 May 10.

Biological Cell Therapy Research Center, Puren Hospital Affiliated to Wuhan University of Science and Technology, 430081, Wuhan, China.

Background: Early diagnosis can significantly improve treatment outcomes for hepatocellular carcinoma (HCC) patients. Currently, the dosage of serum alpha fetoprotein (AFP) is widely used in the diagnosis of HCC, but this biomarker has low specificity and may cause false positive or false negative results. Thus, it's necessary to find and validate other serum tumor markers that in association for AFP would increase the sensitivity and the specificity in the HCC diagnosis. Read More

View Article and Full-Text PDF

Mixed pancreatic hepatoid carcinoma: A surgical case report and literature review.

Int J Surg Case Rep 2021 Apr 30;83:105951. Epub 2021 Apr 30.

Department of Gastrointestinal and Hepato-pancreato-biliary surgery, Bach Mai Hospital, Hanoi, Viet Nam.

Background: Hepatoid carcinoma (HC) is a rare type of malignant tumor that shared similar features of morphology and immunohistochemistry with hepatocellular carcinoma (HCC). Pancreatic HC exists as either pure or mixed type. Mixed pancreatic HC is extremely rare, with only a few cases reported in the literature to date. Read More

View Article and Full-Text PDF

PAF enhances cancer stem cell properties via β-catenin signaling in hepatocellular carcinoma.

Cell Cycle 2021 May 10:1-11. Epub 2021 May 10.

Department of Minimally Invasive Intervention, Shaanxi Provincial Cancer Hospital, Xi'an, China.

Increasing proofs have declared that liver cancer stem cells (CSCs) are the main contributors to tumor initiation, metastasis, therapy resistance, and recurrence of hepatocellular carcinoma (HCC). However, the molecular mechanisms underlying CSCs regulation remain largely unclear. Recently, PCNA-associated factor (PAF) was identified to play a key role in maintaining breast cancer cell stemness, but its role in liver cancer stem cells has not been declared yet. Read More

View Article and Full-Text PDF

TET1 upregulation drives cancer cell growth through aberrant enhancer hydroxymethylation of HMGA2 in hepatocellular carcinoma.

Cancer Sci 2021 May 10. Epub 2021 May 10.

Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

Ten-eleven translocation 1 (TET1) is an essential methylcytosine dioxygenase of the DNA demethylation pathway. Despite its dysregulation being known to occur in human cancer, the role of TET1 remains poorly understood. In this study, we report that TET1 promotes cell growth in human liver cancer. Read More

View Article and Full-Text PDF

Laparoscopic partial liver resection for hepatocellular carcinoma arising from Fontan-associated liver disease: a case report.

Surg Case Rep 2021 May 10;7(1):115. Epub 2021 May 10.

Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan.

Background: The Fontan procedure (FP) is a palliative surgery for functional single ventricle. The Fontan circulation maintains pulmonary circulation by a high central venous pressure, leading to chronic congestive liver. The number of patients diagnosed with hepatocellular carcinoma (HCC) arising from liver fibrosis and cirrhosis after FP is increasing. Read More

View Article and Full-Text PDF

A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints.

Biomater Sci 2021 May 10. Epub 2021 May 10.

The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China. and Fujian Institute of Research on The Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, P. R. China.

T-lymphocytes play a potent role in cancer immunotherapy; while, limited tumor infiltrating lymphocytes (TILs) combined with severe immunosuppression always significantly hinder their antitumor immune responses, especially in solid tumors such as hepatocellular carcinoma (HCC). Here, we prepared a highly stable multifunctional aptamer for strengthening antitumor immunity against HCC solid tumors through a dual immune checkpoint blockade of CTLA-4 and PD-L1. The engineered multifunctional aptamer (termed P1/C4-bi-apt) can block both CTLA-4/B7 and PD-1/PD-L1 signaling pathways and thus enhance the antitumor immune responses. Read More

View Article and Full-Text PDF

Hepatobiliary phase images of gadoxetic acid-enhanced MRI may improve accuracy of predicting the size of hepatocellular carcinoma at pathology.

Acta Radiol 2021 May 8:2841851211014194. Epub 2021 May 8.

Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Medical Imaging, Shanghai, PR China.

Background: Gadoxetic acid-enhanced magnetic resonance imaging (MRI) has been widely used in clinical practice. However, scientific evidence is lacking for recommending a particular sequence for measuring tumor size.

Purpose: To retrospectively compare the size of hepatocellular carcinoma (HCC) measured on different gadoxetic acid-enhanced MRI sequences using pathology as a reference. Read More

View Article and Full-Text PDF

CUL4B facilitates HBV replication by promoting HBx stabilization.

Cancer Biol Med 2021 May 9. Epub 2021 May 9.

Ministry of Education Key Laboratory of Experimental Teratology and Institute of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.

Objective: Hepatitis B virus (HBV) infection is a major public health problem worldwide. However, the regulatory mechanisms underlying HBV replication remain unclear. Cullin 4B-RING ubiquitin E3 ligase (CRL4B) is involved in regulating diverse physiological and pathophysiological processes. Read More

View Article and Full-Text PDF

Amplification of DDR2 mediates Sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma.

Cell Biol Int 2021 May 9. Epub 2021 May 9.

Department of Hepatobiliary Surgery the First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, P.R.China.

Sorafenib was the first systemic therapy approved by the food and drug administration (FDA) to treat advanced hepatocellular carcinoma (HCC). However, Sorafenib therapy is frequently accompanied by drug resistance. We aimed to explore the mechanisms of Sorafenib resistance and provide feasible solutions to increase the response to Sorafenib in patients with advanced HCC. Read More

View Article and Full-Text PDF

Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis.

Ann Surg Oncol 2021 May 9. Epub 2021 May 9.

Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Academia Level 5, 20 College Road, Singapore, 169856, Singapore.

Background: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver with high rates of recurrence post-resection. Repeat hepatectomy (RH) and radiofrequency ablation (RFA) are the mainstays for managing recurrent HCC following initial curative resection. This retrospective study aims to determine the average treatment effect of RH and RFA in patients with recurrent HCC. Read More

View Article and Full-Text PDF

Genotype Distribution of Vitamin D Receptor Polymorphisms among Indonesian Patients with Chronic Hepatitis B.

Rep Biochem Mol Biol 2021 Jan;9(4):463-469

Department of Clinical Pathology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia.

Background: Chronic hepatitis B is a necro-inflammatory of the liver parenchyma caused by hepatitis B virus (HBV) infection leading to liver cirrhosis and hepatocellular carcinoma (HCC). Genetic variants including single nucleotide polymorphisms (SNPs) within genes regulating immune response may contribute to the progression of chronic hepatitis B (CHB) infection. This study aimed to examine the genotype distribution of vitamin D receptor (VDR) polymorphism among patients with CHB infection and to study its association with the development of cirrhosis and hepatoma. Read More

View Article and Full-Text PDF
January 2021

The Comparative Effect of Nisin and Thioridazine as Potential Anticancer Agents on Hepatocellular Carcinoma.

Rep Biochem Mol Biol 2021 Jan;9(4):452-462

Department of Medical Biochemistry & Molecular Biology, Faculty of Medicine, Cairo University.

Background: Hepatocellular carcinoma is a major health problem worldwide especially in Egypt. It accounts for the fifth common cancer and the second cause of death among different cancers. This study investigated the efficacy and molecular mechanism of Nisin and/or Thioridazine as anticancer treatment on human liver cancer HepG2 cell line. Read More

View Article and Full-Text PDF
January 2021

Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma.

Front Mol Biosci 2021 22;8:645084. Epub 2021 Apr 22.

Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.

The purpose of this study was to construct a novel risk scoring model with prognostic value that could elucidate tumor immune microenvironment of hepatocellular carcinoma (HCC). Data were obtained through The Cancer Genome Atlas (TCGA) database. Univariate Cox analysis, least absolute shrinkage and selection operator (LASSO) analysis, and multivariate Cox analysis were carried out to screen for glycolysis-related long noncoding RNAs (lncRNAs) that could provide prognostic value. Read More

View Article and Full-Text PDF

Morphine Suppresses Liver Cancer Cell Tumor Properties and .

Front Oncol 2021 22;11:666446. Epub 2021 Apr 22.

Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Morphine is an analgesic widely adopted to relieve cancer pain. A number of discrepancies, however, are presented by the published literature, with reports suggesting that opioids may either promote or inhibit the spread of cancer. It is of great significance to determine whether morphine may increase the risk of metastasis while utilized in liver cancer surgical treatment. Read More

View Article and Full-Text PDF

The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma.

Front Oncol 2021 21;11:649107. Epub 2021 Apr 21.

Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Hepatocellular carcinoma (HCC) is among the utmost deadly human malignancies. This type of cancer has been associated with several environmental, viral, and lifestyle risk factors. Among the epigenetic factors which contribute in the pathogenesis of HCC is dysregulation of long non-coding RNAs (lncRNAs). Read More

View Article and Full-Text PDF

Congenital heart disease-associated liver disease: a narrative review.

Cardiovasc Diagn Ther 2021 Apr;11(2):577-590

Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.

Congenital heart diseases (CHD) can be associated with liver dysfunction. The cause for liver impairment can result out of a wide spectrum of different causes, including liver congestion, hypoxemia or low cardiac output. Fortunately, most CHD show a good long-term outcome from a cardiac perspective, but great attention should be paid on non-cardiac health problems that develop frequently in patients suffering from CHD. Read More

View Article and Full-Text PDF

Rare Histological Variants of Liver Cancer and Their Management: A Single-Institution Experience.

Case Reports Hepatol 2021 21;2021:6654229. Epub 2021 Apr 21.

Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine/New-York Presbyterian, New York, New York, USA.

Primary liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma, are a major cause of cancer-related morbidity and mortality worldwide. There are several histologically and biologically distinct subtypes of liver cancer that have previously been reported. However, literature regarding the nonsurgical management of these patients upon disease recurrence remains limited. Read More

View Article and Full-Text PDF

Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma.

Oncol Lett 2021 Jun 22;21(6):487. Epub 2021 Apr 22.

Division of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

The association between the serum levels of cancer antigen 125 (CA125; also termed MUC16) and the prognosis of patients with hepatocellular carcinoma (HCC) has not been widely reported to date. The aim of the present study was to determine the association between preoperative serum CA125 levels and prognosis of patients with hepatitis B virus (HBV)-related HCC after hepatectomy. The study included 306 patients with HBV-related HCC who underwent liver resection and were classified into four subgroups based on their baseline CA125 and α-fetoprotein (AFP) levels. Read More

View Article and Full-Text PDF

Protein kinase N1 promotes proliferation and invasion of liver cancer.

Exp Ther Med 2021 Jun 19;21(6):651. Epub 2021 Apr 19.

Department of Radiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China.

Protein kinase (PK) N1, also called PKC-related protein 1, participates in the proliferation, invasion and metastasis of various malignant tumors. However, the role of PKN1 in liver cancer remains to be elucidated. The present study investigated the expression of PKN1 using immunohistochemistry in surgical specimens from 36 patients and analyzed the correlation with VEGF, microvascular density (MVD), cell proliferation index (Ki67) and clinicopathological parameters. Read More

View Article and Full-Text PDF

Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.

Int J Med Sci 2021 30;18(11):2276-2284. Epub 2021 Mar 30.

Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

To develop and validate radiomics nomograms for the pretreatment predictions of overall survival (OS) and time to progression (TTP) in the patients with advanced hepatocellular carcinoma (HCC) treated with apatinib plus transarterial chemoembolization (TACE), and to assess the incremental value of the clinical-radiomics nomograms for estimating individual OS and TTP. A total of 60 patients with advanced HCC (BCLC stage C) treated with apatinib plus TACE were divided into a training set (n=48) and a validation set (n=12). The predictors identified from the clinical variables and the radiomics signature constructed from the computed tomography images, such as ɑ-fetoprotein level (AFP), formfactor, the grey level co-occurrence matrix, the gray level size zone matrix, and the gray level run-length matrix, were used to build the clinical-radiomics nomograms and the radiomics nomograms for the prediction of OS and TTP. Read More

View Article and Full-Text PDF